Peptides for Weight Loss
Evidence-based overview of peptides studied for weight loss and obesity. GLP-1 agonists, metabolic peptides, and research findings.
Research Overview
Weight loss peptide research has dramatically accelerated since the FDA approval of semaglutide (Wegovy) in 2021. The GLP-1 receptor agonist class has demonstrated unprecedented efficacy in clinical trials, with some agents showing 15-25% total body weight loss in randomized controlled trials.
Beyond GLP-1 agonists, newer dual and triple agonists (GIP/GLP-1, GIP/GLP-1/glucagon) are showing even greater potential. Tirzepatide, retatrutide, and survodutide represent the next generation of weight loss peptides with multi-receptor mechanisms that may address metabolic dysfunction through complementary pathways.
Research also continues on non-incretin peptides including AOD-9604 (a growth hormone fragment) and various metabolic regulators, though evidence quality varies significantly. This page aggregates peptides with peer-reviewed research relevant to weight management.
Key Research Findings
The weight loss peptide landscape has been transformed by GLP-1 receptor agonists. Key findings include:
- Semaglutide (Wegovy): 14.9% mean weight loss at 68 weeks in STEP 1 trial
- Tirzepatide (Zepbound): 20.9% mean weight loss at 72 weeks in SURMOUNT-1
- Retatrutide: 24.2% mean weight loss at 48 weeks in Phase 2 trial
Evidence Hierarchy
| Evidence Level | Peptide Examples |
|---|---|
| High | Semaglutide, Tirzepatide, Liraglutide |
| Moderate | Retatrutide, Survodutide, Cagrilintide |
| Low | AOD-9604, Various GHRPs |
| Very Low | Emerging peptides in early research |
Mechanism Classes
GLP-1 Receptor Agonists
Glucagon-like peptide-1 agonists reduce appetite, slow gastric emptying, and improve glycemic control. This is the most thoroughly researched peptide class for weight management.
Dual Agonists (GIP/GLP-1)
Tirzepatide and similar compounds target both GIP and GLP-1 receptors, potentially offering synergistic metabolic benefits beyond single-receptor agonists.
Triple Agonists (GIP/GLP-1/Glucagon)
Retatrutide and amycretin add glucagon receptor agonism, theoretically increasing energy expenditure and fat oxidation while maintaining appetite suppression.
Growth Hormone Fragments
AOD-9604 and related fragments represent an older research approach with limited human trial data compared to incretin-based therapies.
Peptides Studied for Weight Loss
Semaglutide
HighA GLP-1 receptor agonist FDA-approved for type 2 diabetes, obesity, cardiovascular risk reduction, and MASH. Among the most extensively studied peptides with robust Phase 3 data demonstrating significant metabolic, cardiovascular, renal, and hepatic benefits.
Tirzepatide
HighA dual GIP/GLP-1 receptor agonist approved globally for type 2 diabetes (Mounjaro), weight management (Zepbound), and obstructive sleep apnea. Extensive clinical trial data from 30+ countries demonstrates significant effects on glycemic control, body weight, and cardiovascular outcomes.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. The peptides listed may or may not have regulatory approval. Always consult a qualified healthcare provider before making any health decisions.